Deutsche Bank
FATE icon

Deutsche Bank’s Fate Therapeutics FATE Stock Holding History

Deutsche Bank’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$110K Hold
91,679
– – ﹤0.01% 3236
2025
Q4 		$89.8K Sell
91,679
-65,480
-42% -$78.6K ﹤0.01% 3324
2025
Q3 		$198K Buy
+157,159
New +$169K ﹤0.01% 3067
2024
Q4 		– Sell
-55,663
Closed -$195K – 3637
2024
Q3 		$195K Buy
55,663
+22,210
+66% +$86.4K ﹤0.01% 2941
2024
Q2 		$110K Sell
33,453
-6,529
-16% -$28.6K ﹤0.01% 3079
2024
Q1 		$293K Buy
39,982
+2,157
+6% +$13.4K ﹤0.01% 2621
2023
Q4 		$141K Sell
37,825
-6,894
-15% -$16.3K ﹤0.01% 3053
2023
Q3 		$94.8K Sell
44,719
-200,711
-82% -$665K ﹤0.01% 3181
2023
Q2 		$1.17M Buy
245,430
+184,922
+306% +$1.02M ﹤0.01% 1905
2023
Q1 		$345K Sell
60,508
-173,170
-74% -$1.04M ﹤0.01% 2708
2022
Q4 		$2.36M Buy
233,678
+10,674
+5% +$200K ﹤0.01% 1563
2022
Q3 		$5M Buy
223,004
+84,915
+61% +$2.45M ﹤0.01% 1205
2022
Q2 		$3.42M Sell
138,089
-10,745
-7% -$296K ﹤0.01% 1476
2022
Q1 		$5.77M Sell
148,834
-3,628
-2% -$140K ﹤0.01% 1343
2021
Q4 		$8.92M Sell
152,462
-656,148
-81% -$37.2M ﹤0.01% 1157
2021
Q3 		$47.9M Buy
808,610
+16,549
+2% +$1.3M 0.02% 621
2021
Q2 		$68.7M Buy
792,061
+620,999
+363% +$50M 0.03% 503
2021
Q1 		$14.1M Buy
171,062
+112,930
+194% +$10.8M 0.01% 1032
2020
Q4 		$5.29M Sell
58,132
-86,887
-60% -$5.4M ﹤0.01% 1332
2020
Q3 		$5.8M Sell
145,019
-194,622
-57% -$6.8M ﹤0.01% 1202
2020
Q2 		$11.7M Buy
339,641
+267,825
+373% +$7.98M 0.01% 909
2020
Q1 		$1.59M Buy
71,816
+49,283
+219% +$1.25M ﹤0.01% 1839
2019
Q4 		$440K Buy
22,533
+4,444
+25% +$70.6K ﹤0.01% 2789
2019
Q3 		$280K Sell
18,089
-3,759
-17% -$72.1K ﹤0.01% 2984
2019
Q2 		$442K Sell
21,848
-99,792
-82% -$1.8M ﹤0.01% 3352
2019
Q1 		$2.14M Buy
121,640
+94,759
+353% +$1.5M ﹤0.01% 2454
2018
Q4 		$343K Sell
26,881
-183,691
-87% -$2.56M ﹤0.01% 3569
2018
Q3 		$3.43M Buy
210,572
+113,386
+117% +$1.34M ﹤0.01% 2480
2018
Q2 		$1.1M Buy
97,186
+31,899
+49% +$351K ﹤0.01% 3357
2018
Q1 		$635K Sell
65,287
-21,244
-25% -$204K ﹤0.01% 3582
2017
Q4 		$527K Buy
86,531
+51,433
+147% +$229K ﹤0.01% 3566
2017
Q3 		$138K Sell
35,098
-8,827
-20% -$30K ﹤0.01% 4048
2017
Q2 		$141K Buy
+43,925
New +$168K ﹤0.01% 4088
2016
Q3 		– Sell
-17,792
Closed -$30K – 5005
2016
Q2 		$30K Sell
17,792
-25,663
-59% -$46.5K ﹤0.01% 4620
2016
Q1 		$78K Buy
43,455
+36,985
+572% +$76.2K ﹤0.01% 4136
2015
Q4 		$21K Sell
6,470
-7,330
-53% -$30.8K ﹤0.01% 4739
2015
Q3 		$73K Sell
13,800
-12,042
-47% -$82.3K ﹤0.01% 4239
2015
Q2 		$166K Buy
25,842
+11,072
+75% +$66.2K ﹤0.01% 3974
2015
Q1 		$72K Sell
14,770
-16,026
-52% -$79.4K ﹤0.01% 4261
2014
Q4 		$154K Buy
30,796
+4,113
+15% +$18.2K ﹤0.01% 4443
2014
Q3 		$135K Buy
26,683
+1,982
+8% +$11.5K ﹤0.01% 4315
2014
Q2 		$154K Buy
24,701
+7,796
+46% +$54.9K ﹤0.01% 4298
2014
Q1 		$164K Sell
16,905
-1,595
-9% -$12.3K ﹤0.01% 3995
2013
Q4 		$115K Buy
+18,500
New +$116K ﹤0.01% 3994

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deutsche Bank's FATE Position: Q1 2026 in Review

Deutsche Bank held its Fate Therapeutics (FATE) position steady in Q1 2026 at 91,679 shares worth $110K. The position accounts for ﹤0.01% of the portfolio, ranked #3236.

Deutsche Bank first reported a position in FATE in Q4 2013 and has held it in 44 quarters since. The position peaked at $68.7M in Q2 2021. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • Deutsche Bank held 91,679 shares of Fate Therapeutics worth $110K as of Q1 2026.
  • Deutsche Bank left its Fate Therapeutics share count unchanged in Q1 2026.
  • Fate Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q1 2026, its #3236 holding.
  • Deutsche Bank first reported a position in Fate Therapeutics in Q4 2013 and has held it in 44 quarters since.
  • Deutsche Bank's Fate Therapeutics position peaked at $68.7M in Q2 2021.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.